


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1. (Currently amended): A compound of the formula



in which

R<sub>1</sub> is CH(R<sub>c</sub>)C(=O)N(R<sub>a</sub>)R<sub>b</sub> or (CH<sub>2</sub>)<sub>k</sub>N(R<sub>c</sub>)R<sub>d</sub>, wherein

k is 0, 1 or 2;

R<sub>a</sub> and R<sub>b</sub>, independently, are hydrogen or an optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl or heteroaryl(C<sub>1-4</sub>)alkyl group,

R<sub>c</sub> and R<sub>d</sub>, independently, are hydrogen or an optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl, aryl, aryl(C<sub>1-4</sub>)alkyl, heteroaryl, heteroaryl(C<sub>1-4</sub>)alkyl, chroman-4-yl, isochroman-4-yl, thiochroman-4-yl, isothiochroman-4-yl, 1,1-dioxo-1λ<sup>6</sup>-thiochroman-4-yl, 2,2-dioxo-2λ<sup>6</sup>-isothiochroman-4-yl, 1,2,3,4-tetrahydro-quinolin-4-yl, 1,2,3,4-tetrahydro-isoquinolin-4-yl, 1,2,3,4-tetrahydro-naphthalen-1-yl, 1,1-dioxo-1,2,3,4-tetrahydro-1λ<sup>6</sup>-benzo[e][1,2]thiazin-4-yl, 2,2-dioxo-1,2,3,4-tetrahydro-2λ<sup>6</sup>-benzo[c][1,2]thiazin-4-yl, 1,1-dioxo-3,4-dihydro-1H-1λ<sup>6</sup>-benzo[c][1,2]oxathiin-4-yl, 2,2-dioxo-3,4-dihydro-2H-2λ<sup>6</sup>-benzo[e][1,2]oxathiin-4-yl, 2,3,4,5-tetrahydro-benzo[b]oxepin-5-yl or 1,3,4,5-tetrahydro-benzo[c]oxepin-5-yl group, or

R<sub>a</sub> and R<sub>b</sub>, or R<sub>c</sub> and R<sub>d</sub>, together with the nitrogen to which they are attached, form an optionally substituted pyrrolidinyl, 1-piperidinyl, 4-morpholinyl or piperazinyl group; and

R<sub>e</sub> is optionally substituted (C<sub>1-8</sub>)alkyl, (C<sub>1-4</sub>)alkoxy(C<sub>1-4</sub>)alkyl, (C<sub>3-7</sub>)cycloalkyl or (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkyl;

R<sub>2</sub> is hydrogen or (C<sub>1-4</sub>)alkyl;

R<sub>3</sub> is hydrogen, (C<sub>1-6</sub>)alkyl or an optionally substituted (C<sub>1-6</sub>)alkylOC(=O)NH, (C<sub>3-7</sub>)cycloalkylOC(=O)NH, (C<sub>3-7</sub>)cycloalkyl(C<sub>1-4</sub>)alkylOC(=O)NH, aryl(C<sub>1-4</sub>)alkylOC(=O)NH, heteroaryl(C<sub>1-4</sub>)alkylOC(=O)NH, (C<sub>1-4</sub>)alkylC(=O)NH, (C<sub>3-7</sub>)cycloalkylC(=O)NH, arylC(=O)NH, aryl(C<sub>1-4</sub>)alkylC(=O)NH, heteroarylC(=O)NH or heteroaryl(C<sub>1-4</sub>)alkylC(=O)NH group;

U is a bond, ~~CF<sub>2</sub>, CF<sub>2</sub>CF<sub>2</sub>, CHF, CHFCHF, cycloprop-1,2-ylene, (C<sub>1-3</sub>)alkylenoxy, (C<sub>1-8</sub>)alkylene, NR<sub>g</sub> or an aromatic or heteroaromatic ring, which ring is optionally substituted with halogen, (C<sub>1-4</sub>)alkoxy, hydroxy or (C<sub>1-4</sub>)alkyl, whereby Z and V are in ortho or meta position to each other, wherein~~

~~R<sub>g</sub> is hydrogen, (C<sub>1-8</sub>)alkyl or (C<sub>3-7</sub>)cycloalkyl;~~

V is CH=CH, ~~cycloprop-1,2-ylene~~, CH<sub>2</sub>CH(OH), CH(OH)CH<sub>2</sub> or CR<sub>h</sub>R<sub>h</sub>CR<sub>h</sub>R<sub>h</sub>, wherein each R<sub>h</sub>, independently, is hydrogen, fluorine or (C<sub>1-4</sub>)alkyl;

W is (C<sub>1-6</sub>)alkylene, ~~O, S, S(=O)<sub>2</sub>, C(=O), C(=O)O, OC(=O), N(R<sub>f</sub>)C(=O), C(=O)NR<sub>f</sub> or NR<sub>f</sub>, wherein~~

~~R<sub>f</sub> is hydrogen or (C<sub>1-4</sub>)alkyl;~~

X is an optionally substituted (C<sub>1-4</sub>)alkanylylidene ~~[[,]] or (C<sub>1-4</sub>)alkylene, (C<sub>3-7</sub>)cycloalkylene, piperidin-diyl, pyrrolidin-diyl, benzothiazole-4,6-diyl, benzoxazole-4,6-diyl, 1H-benzotriazole-4,6-diyl, imidazo[1,2-a]pyridine-6,8-diyl, benzo[1,2,5]oxadiazole-4,6-diyl, benzo[1,2,5]thiadiazole-4,6-diyl, 1H-indole-5,7-diyl, 1H-indole-4,6-diyl, 1H-benzimidazole-4,6-diyl or 1H-indazole-1,6-diyl group or an optionally substituted aromatic or heteroaromatic ring, whereby Y and C(=O)NR<sub>2</sub> are in meta position to each other;~~

Y is a bond, ~~O, S(=O)<sub>2</sub>, S(=O)<sub>2</sub>NR<sub>g</sub>, N(R<sub>g</sub>)S(=O)<sub>2</sub>, NR<sub>g</sub>, C(R<sub>g</sub>)OH, C(=O)NR<sub>g</sub> [[,]] or N(R<sub>g</sub>)C(=O), C(=O)N(R<sub>g</sub>)O or ON(R<sub>g</sub>)C(=O), wherein~~


$R_g$  is hydrogen,  $(C_{1-8})$ alkyl or  $(C_{3-7})$ cycloalkyl;

Z is ~~O, CH<sub>2</sub>, CF<sub>2</sub>, CHF, cycloprop-1,2-ylene~~ or a bond; and

n is 0 to 5,

the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form.

Claim 2. (Original): A process for the preparation of a compound as defined in claim 1 of the formula I, in free base form or in acid addition salt form, comprising the steps of cyclisation by metathesis of a compound of the formula



in which  $R_1$ ,  $R_2$ ,  $R_3$ , U, W, X, Y, Z and n are as defined for the formula I, in the presence of a catalyst, for instance a ruthenium, tungsten or molybdenum complex, optionally followed by reduction, oxidation or functionalisation of the resulting carbon-carbon-double bond, and of recovering the so obtainable compound of the formula I in free base form or in acid addition salt form.

Claim 3. (Canceled)

Claim 4. (Canceled)

Claim 5. (Original): A pharmaceutical composition comprising a compound as claimed in claim 1, in free base form or in pharmaceutically acceptable acid addition salt form, as active ingredient and a pharmaceutical carrier or diluent.

Claim 6-9. (Canceled)